Dr Audrey Kong presents PARTNER trial at IDF 2026
Congratulations to Dr Yee Wen Kong on her presentation at the IDF, ADC and Metabolic Diseases Congress in Melbourne, where she was selected to present at the Korean and Australian Diabetes Societies Joint Symposium. Dr Kong discussed the benefits and risks of SGLT inhibitors, which is a type of medication that helps lower blood sugar by helping the kidneys remove more glucose through urine, but is not approved due to increased risk of diabetic ketoacidosis (DKA) in people with type 1 diabetes. Dr Kong shared how this therapy may be made safer for use in people with type 1 diabetes through strategies to manage and reduce the risk of potential DKA.
Dr Audrey Kong presents PARTNER trial at IDF & ADC 2026
Congratulations to Dr Yee Wen Kong on her presentation at the IDF, ADC and Metabolic Diseases Congress in Melbourne, where she was selected to present at the Korean and Australian Diabetes Societies Joint Symposium. Dr Kong discussed the benefits and risks of SGLT inhibitors, which is a type of medication that helps lower blood sugar by helping the kidneys remove more glucose through urine, but is not approved due to increased risk of diabetic ketoacidosis (DKA) in people with type 1 diabetes. Dr Kong shared how this therapy may be made safer for use in people with type 1 diabetes through strategies to manage and reduce the risk of potential DKA.